clinical 3,114 words KG: ent-clin-fde6c2e3 2026-03-30
kind:clinical-trialsection:clinical-trialscondition:parkinsons-diseaseintervention:drugsponsor:neuroderm-ltdstatus:completedphase:phase-3
Contents

ND0612 Subcutaneous Levodopa Infusion PD Trial (NCT04006210)

Knowledge Graph

Related Hypotheses (12)

Synthetic Biology Approach: Designer Mitochondrial Export Sy
Score: 0.36
Magnetosonic-Triggered Transferrin Receptor Clustering
Score: 0.47
Pericyte Contractility Reset via Selective PDGFR-β Agonism
Score: 0.44
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59

Related Analyses (2)

Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived

Related Experiments (6)

Cytochrome Therapeutics
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40
Non-Motor Symptom Progression in Parkinson's Disease — Mecha
clinical · proposed · Score: 0.40